Cargando…
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
Health technology assessment (HTA) can be used to make healthcare systems more equitable and efficient. Advances in precision oncology are challenging conventional thinking about HTA. Precision oncology advances are rapid, involve small patient groups, and are frequently evaluated without a randomiz...
Autores principales: | Regier, Dean A., Pollard, Samantha, McPhail, Melanie, Bubela, Tania, Hanna, Timothy P., Ho, Cheryl, Lim, Howard J., Chan, Kelvin, Peacock, Stuart J., Weymann, Deirdre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596463/ https://www.ncbi.nlm.nih.gov/pubmed/36284134 http://dx.doi.org/10.1038/s41698-022-00316-1 |
Ejemplares similares
-
The Importance of and Challenges with Adopting Life-Cycle Regulation and Reimbursement in Canada
por: McPhail, Melanie, et al.
Publicado: (2022) -
Should Canada adopt managed access agreements in Canada for expensive drugs?
por: McPhail, Melanie, et al.
Publicado: (2023) -
Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness
por: McPhail, Melanie, et al.
Publicado: (2022) -
Lessons from Canada’s notice of compliance with conditions policy for the life-cycle regulation of drugs
por: McPhail, Melanie, et al.
Publicado: (2023) -
Stakeholder Perspectives on Navigating Evidentiary and Decision Uncertainty in Precision Oncology
por: Pollard, Samantha, et al.
Publicado: (2022)